PartnerRe Corrects EXOR’s Misleading Press Release on PartnerRe’s Preferred Shares
S&P Has Not Provided a View on PartnerRe’s Ratings in Relation to a Potential Sale to EXOR
S&P Has Provided a View on EXOR’s Ratings – It has Revised its Outlook on EXOR’s Ratings to “Negative”
The
PEMBROKE,
S&P Has NOT Provided a View on PartnerRe’s Ratings in Relation to a Sale to EXOR
- S&P has not taken a view nor has it made any public statements regarding the credit or financial strength ratings of
PartnerRe in the event of an EXOR acquisition. EXOR’s statements with regard to PartnerRe’s potential credit ratings are misleading, and do not reflect the views of S&P or S&P’s analyst forPartnerRe . -
PartnerRe does not anticipate that S&P will comment on the potential rating implications of a hypothetical EXOR acquisition ofPartnerRe unless and until a definitive merger agreement is in place.
S&P Has Provided a View on EXOR’s Ratings in Relation to a Potential Acquisition of
- S&P revised its outlook on EXOR’s credit rating to “Negative” following its unsolicited offer to acquire
PartnerRe due to EXOR’s increased indebtedness associated with financing the proposed acquisition.As S&P stated on
April 17, 2015 : “The [EXOR] negative outlook reflects our view that if thePartnerRe acquisition is completed, EXOR’s LTV [loan-to-value] may exceed our 20% threshold for the ratings. It also reflects our view that EXOR’s listed assets may fall below 60% of total assets, which we believe would not be commensurate with our current assessment of a ‘satisfactory’ business risk profile.”
S&P Has Affirmed PartnerRe’s Ratings With a Stable Outlook in the Context of the AXIS Merger
As S&P stated on
The preferred shares of the merged
A potential sale of
- Unlike common shareholders, perpetual preferred shareholders and creditors would retain a continuing interest in
PartnerRe post-acquisition by EXOR. - Preferred shares would be a fundamentally different security if
PartnerRe were owned by EXOR vs. merged with AXIS:- Wholly owned subsidiary of diversified financial investor vs. independent enterprise solely focused on reinsurance / insurance.
- Directly exposed to parent company decisions about management, dividend policy, enterprise risk profile which may be driven by factors extraneous to insurance markets.
- Indirectly exposed to financial condition of sister companies Fiat Chrysler Automobiles (“FCA”) and CNH Industrial – non-investment grade rated industrial entities that are marginally profitable and capital intensive and cyclical.
- More limited access to capital following a major catastrophe as a wholly-owned subsidiary of EXOR vs. remaining as a publicly listed company when merged with AXIS.
- Notwithstanding EXOR’s assertions, PartnerRe’s credit standing and ratings will be impacted by developments at EXOR and vice versa.
- Rating agency communications are clear on this point and are supported by rating methodologies for operating holding companies.
The PartnerRe Board of Directors continues to urge its shareholders of both common and preferred shares to promptly use the white proxy card to vote FOR the Amalgamation Agreement with AXIS Capital at the Shareholder Meeting on
Additional information is available on PartnerRe’s website and on www.partnerre-valuecreation.com.
_____________________________________________
About
Important Information For Investors And Shareholders
This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed business combination between
Participants in Solicitation
These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the joint proxy statement/prospectus and other relevant materials filed with the
Forward Looking Statements
Certain statements in this communication regarding the proposed transaction between
• the failure to obtain the approval of shareholders of
• the failure to consummate or delay in consummating the proposed transaction for other reasons;
• the timing to consummate the proposed transaction;
• the risk that a condition to closing of the proposed transaction may not be satisfied;
• the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained, or is obtained subject to conditions that are not anticipated;
• AXIS’ or PartnerRe’s ability to achieve the synergies and value creation contemplated by the proposed transaction;
• the ability of either
• the diversion of management time on transaction-related issues.
PartnerRe’s forward-looking statements are based on assumptions that
View source version on businesswire.com: http://www.businesswire.com/news/home/20150623006021/en/
Investor:
[email protected]
or
Media:
[email protected]
or
Sard Verbinnen & Co
Source:



Advisor News
- Will rising retirement needs spark an annuity boom?
- Living longer, retiring poorer: Why fragmented systems are failing Americans
- Women say their advisors respect them, but talk down to them
- How PEPs compare with traditional 401(k)s
- Allianz studies why 42% of Americans retire sooner than expected
More Advisor NewsAnnuity News
- Fortitude Re Completes $500 Million FABN Issuance
- Reframing retirement income for greater certainty
- Jackson Introduces Dow Jones Industrial Average Index Option, Flexible Premiums, Six-Year Rate Guarantee in Latest Registered Index-Linked Annuity Launch
- Senior Market Sales® Fortifies Annuity Reach With Acquisition of Retirement Planning Firm Stratton & Company
- NAIC regulators continue pushing for annuity illustration updates
More Annuity NewsHealth/Employee Benefits News
- Affordable Care Act enrollment in Illinois continues to drop, new state data shows
- Clark County residents warned to brace for health insurance rate hikes next year
- Researchers at Memorial Sloan-Kettering Cancer Center Describe Findings in Clinical Oncology (Impact of health insurance coverage on dentition status prior to hematopoietic cell transplant: A 10-year single-institution observational study): Clinical Oncology
- Colorado lupus patients can't afford 'most favored nation' drug pricing | PODIUM
- Molina Healthcare Wins Illinois Medicaid Contract
More Health/Employee Benefits NewsLife Insurance News
- Greg Lindberg moves to halt $1.65B restitution order, claims he ‘overpaid’
- Fidelity Investments® to Expand Target Date Lineup With Launch of Guaranteed Income Solution
- KBRA Releases Research – Private Credit: Much Ado About Nothing – Perspectives on Columbia Business School Paper About Private Ratings
- VUL sales skyrocket in Q1, signaling major market shift
- KBRA Releases Research – Private Credit: A More Balanced Review of the NAIC PLR Review Process for Insurance Balance Sheets
More Life Insurance News